HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. The piece reads, “‘We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection,’ the February 2026 report states. The report highlights a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, which resolved an earlier regulatory setback and allowed HeartBeam to transition to commercial-stage status.”
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer